Angiotensin type 2 receptors: blood pressure regulation and end organ damage

Colin Sumners; Annette D. de Kloet; Eric G. Krause; Thomas Unger; Ulrike Muscha Steckelings

doi:10.1016/j.coph.2015.01.004

Angiotensin type 2 receptors: blood pressure regulation and end organ damage

Colin Sumners, Annette D. de Kloet, Eric G. Krause, Thomas Unger, Ulrike Muscha Steckelings^*

^*Corresponding author for this work

Bedrijfsbureau CARIM

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In most situations, the angiotensin AT2-receptor (AT2R) mediates physiological actions opposing those mediated by the AT1-receptor (AT1R), including a vasorelaxant effect. Nevertheless, experimental evidence vastly supports that systemic application of AT2R-agonists is blood pressure neutral. However, stimulation of AT2R locally within the brain or the kidney apparently elicits a systemic blood pressure lowering effect. A systemic effect of AT2R stimulation on blood pressure can also be achieved, when the prevailing effect of continuous background AT1R-stimulation is attenuated by low-dose AT1R blockade. Despite a lack of effect on blood pressure, AT2R stimulation still protects from hypertensive end-organ damage. Current data and evidence therefore suggest that AT2R agonists will not be suitable as future antihypertensive drugs, but that they may well be useful for end-organ protection in combination with established anti-hypertensives.

Original language	English
Pages (from-to)	115-121
Journal	Current Opinion in Pharmacology
Volume	21
DOIs	https://doi.org/10.1016/j.coph.2015.01.004
Publication status	Published - Apr 2015

Access to Document

10.1016/j.coph.2015.01.004

Cite this

@article{7b8b989c8c2f4e6c94deae5d3943f77e,

title = "Angiotensin type 2 receptors: blood pressure regulation and end organ damage",

abstract = "In most situations, the angiotensin AT2-receptor (AT2R) mediates physiological actions opposing those mediated by the AT1-receptor (AT1R), including a vasorelaxant effect. Nevertheless, experimental evidence vastly supports that systemic application of AT2R-agonists is blood pressure neutral. However, stimulation of AT2R locally within the brain or the kidney apparently elicits a systemic blood pressure lowering effect. A systemic effect of AT2R stimulation on blood pressure can also be achieved, when the prevailing effect of continuous background AT1R-stimulation is attenuated by low-dose AT1R blockade. Despite a lack of effect on blood pressure, AT2R stimulation still protects from hypertensive end-organ damage. Current data and evidence therefore suggest that AT2R agonists will not be suitable as future antihypertensive drugs, but that they may well be useful for end-organ protection in combination with established anti-hypertensives.",

author = "Colin Sumners and {de Kloet}, {Annette D.} and Krause, {Eric G.} and Thomas Unger and Steckelings, {Ulrike Muscha}",

year = "2015",

month = apr,

doi = "10.1016/j.coph.2015.01.004",

language = "English",

volume = "21",

pages = "115--121",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Angiotensin type 2 receptors: blood pressure regulation and end organ damage

AU - Sumners, Colin

AU - de Kloet, Annette D.

AU - Krause, Eric G.

AU - Unger, Thomas

AU - Steckelings, Ulrike Muscha

PY - 2015/4

Y1 - 2015/4

N2 - In most situations, the angiotensin AT2-receptor (AT2R) mediates physiological actions opposing those mediated by the AT1-receptor (AT1R), including a vasorelaxant effect. Nevertheless, experimental evidence vastly supports that systemic application of AT2R-agonists is blood pressure neutral. However, stimulation of AT2R locally within the brain or the kidney apparently elicits a systemic blood pressure lowering effect. A systemic effect of AT2R stimulation on blood pressure can also be achieved, when the prevailing effect of continuous background AT1R-stimulation is attenuated by low-dose AT1R blockade. Despite a lack of effect on blood pressure, AT2R stimulation still protects from hypertensive end-organ damage. Current data and evidence therefore suggest that AT2R agonists will not be suitable as future antihypertensive drugs, but that they may well be useful for end-organ protection in combination with established anti-hypertensives.

AB - In most situations, the angiotensin AT2-receptor (AT2R) mediates physiological actions opposing those mediated by the AT1-receptor (AT1R), including a vasorelaxant effect. Nevertheless, experimental evidence vastly supports that systemic application of AT2R-agonists is blood pressure neutral. However, stimulation of AT2R locally within the brain or the kidney apparently elicits a systemic blood pressure lowering effect. A systemic effect of AT2R stimulation on blood pressure can also be achieved, when the prevailing effect of continuous background AT1R-stimulation is attenuated by low-dose AT1R blockade. Despite a lack of effect on blood pressure, AT2R stimulation still protects from hypertensive end-organ damage. Current data and evidence therefore suggest that AT2R agonists will not be suitable as future antihypertensive drugs, but that they may well be useful for end-organ protection in combination with established anti-hypertensives.

U2 - 10.1016/j.coph.2015.01.004

DO - 10.1016/j.coph.2015.01.004

M3 - Article

SN - 1471-4892

VL - 21

SP - 115

EP - 121

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

ER -